Quince Therapeutics: directors resign and replacements named

What happened

• The filing reports that on Sep 30, 2026, June Bray, David Lamond and Christopher Senner "tendered conditional resignations" from the board of directors, each effective as of two business days following the conclusion of the Company’s Special Meeting of Stockholders, which will be held on Oct 6, 2026, and contingent upon stockholder approval of three proposals (the "Effective Time").
• The filing reports that on Oct 1, 2026 the board approved the conditional appointments of Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise to the board, each to be effective at the Effective Time. The filing states the resignations were not the result of any disagreement with the Company.

Key details

• The resignations are contingent on approval of three Required Company Stockholder Proposals: the Conversion Proposal, the Minimum Price Proposal and the Authorized Shares Proposal.
• The Authorized Shares Proposal would increase authorized shares of common stock from 250,000,000 to 275,000,000. The Conversion Proposal involves issuance of shares that "will represent more than 20% of the shares of common stock outstanding" under Nasdaq Listing Rule 5635(a).
• Expected committee assignments at the Effective Time: Leone Patterson (chair, audit committee; chair, compensation committee), Catherine Bonuccelli (audit committee; compensation committee), James Valentine (chair, nominating and corporate governance committee; audit committee member), Drayton Wise (nominating and corporate governance committee member).

Why it may matter

• The filing is reported under Item 5.02 (Departure of directors or certain officers; election of directors), which covers board resignations and appointments. This filing does not show why the insider traded or why the company acted.